Phase 1: Validation and Co-development

TRx has initially focussed on establishing and progressing its technology in a series of focussed co-development product programmes:
  • Molecules and diseases have been selected with strong relevance to TRx platform benefits
  • Co-development programmes have moved through technology and value inflection points and rapidly on to clinic
Our co-development phase is well established, creating both value and a secure technology evidence base.

Phase 2: Technology Exploitation

TRx is now developing a wholly-owned pipeline in CNS, cancer & respiratory disease.

  • Emerging co-development data supports pipeline selection and development strategy
  • Focus on high unmet need, clinical viability and therapeutic innovation
  • Build an experienced team, progressing a series of programmes to optimal out-licensing value

Independent development of assets has commenced following closure of our first funding round. TRx is targeting a Series A fundraise during late 2022 enabling entry to clinic.